The Association of Chlamydia pneumonia and Helicobacter pylori IgG Seropositivity With Omentin-1, Visfatin and Adiponectin Levels in Postmenopausal Women
Abstract
Some adipocytokines are cardioprotective or pro-inflammatory for cardiovascular system. Chronic infection with Chlamydia pneumoniae and Helicobacter pylori has been also considered as novel risk factors for atherosclerosis. The main aim of the current population-based study is to investigate the potential link between circulating adipocytokines and Chlamydia pneumoniae or Helicobacter pylori IgG seropositivities. A total of 250 healthy postmenopausal women who participated in a prospective cohort study were evaluated for IgG antibodies directed against C.pneumoniae and H. pylori. Omentin-1, visfatin, adiponectin, and high sensitivity C-reactive protein were measured by highly specific enzyme-linked immunosorbent assay methods. The prevalence of IgG antibodies against C. pneumoniae and H. pylori among the studied population was 20.4% (51 women) and 57.2% (143 women), respectively. There were no significant differences in adipocytokine levels between H. pylori IgG seropositive and H. pylori seronegative subjects. Similar results for visfatin and omentin-1 were found when C. pneumoniae IgG seropositive were compared with C. pneumoniae IgG seronegative subjects. However, in general linear model adjusted for age, body mass index and hs-CRP levels revealed significant difference between C. pneumoniae seropositive and C. pneumoniae seronegative subjects for circulating adiponectin. In conclusion, Chlamydia pneumoniae IgG seropositivity was associated with higher adiponectin levels in postmenopausal women. The elucidation of interaction mechanism of Chlamydia pneumoniae and a cardioprotective adipocytokine (adiponectin) will be useful in future therapeutic strategies.
Wronkowitz N, Romacho T, Sell H, Eckel J. Adipose tissue and inflammation in cardiovascular disease. Front
Horm Res 2014;43:79-92.
Yoo HJ, Choi KM. Adipokines as a novel link between obesity and atherosclerosis. World J Diabetes 2014;5:357-63.
Ntaios G, Gatselis NK, Makaritsis K, Dalekos GN.Adipokines as mediators of endothelial function and atherosclerosis. Atherosclerosis 2013;227:216-21.
Brochu-Gaudreau K, Rehfeldt C, Blouin R, Bordignon V,Murphy BD, Palin MF. Adiponectin action from head to toe. Endocrine 2010;37:11-32.
Choi HY, Kim S, Yang SJ, Yoo SJ, Seo JA, Kim SG, et al. Association of adiponectin,resistin,and vascular inflammation: analysis with 18-fluorodeoxyglucose positron emission tomography. Arterioscler Thromb Vasc Biol 2011;31:944-9.
Ouchi N, Shibata R, Walsh K. Cardioprotection by adiponectin. Trends Cardiovasc Med 2006;16:141-6.
Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004;291:1730-7.
Katsi V, Vamvakou G, Lekakis J, Tousoulis D, Stefanadis C, Makris T, et al. Omentin, Fat and Heart: Classical Music with New Instruments. Heart Lung Circ 2014;23:802-6.
Greulich S, Chen WJ, Maxhera B, Rijzewijk LJ, van der Meer RW, Jonker JT, et al. Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies. PloS one 2013;8:e59697.
Tan BK, Adya R, Farhatullah S, Lewandowski KC, O'Hare P, Lehnert H, et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovarian syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008;57:801-8.
Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, et al. Visceral adipose tissue derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A 2005;102:10610-5.
Wang XH, Dou LZ, Gu C, Wang XQ.Plasma levels of omentin-1 and visfatin in senile patients with coronary heart disease and heart failure. Asian Pac J Trop Med 2014;7:55-62.
Pala L, Monami M, Ciani S, Dicembrini I, Pasqua A, Pezzatini A, et al. Adipokines as possible new predictors of cardiovascular diseases: a case control study. J Nutr Metab 2012;2012:253428.
Wang P, Vanhoutte PM, Miao CY. Visfatin and cardio- cerebro-vascular disease. J Cardiovasc Pharmacol 2012;59:1-9.
Rupprecht HJ, Blankenberg S, Bickel C, Rippin G, Hafner G, Prellwitz W, et al. Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation 2001;104:25-31.
Vercellotti GM. Overview of infections and cardiovascular diseases. J Allergy Clin Immunol 2001;108:S117-20.
Kol A, Libby P. The mechanisms by which infectious agents may contribute to atherosclerosis and its clinical manifestations. Trends Cardiovasc Med 1998;8:191-9.
Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Makela PH, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1998;2:983-6.
Ngeh J, Anand V, Gupta S. Chlamydia pneumoniae and atherosclerosis - what we know and what we don't. Clin Microbiol Infect 2002;8:2-13.
Ramirez JA. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group. Ann Intern Med 1996;125:979-82.
Sharma V, Aggarwal A. Helicobacter pylori:Does it add to risk of coronary artery disease. World J cardiol 2015;7:19-25.
Heuschmann PU, Neureiter D, Gesslein M, Craiovan B, Maass M, Faller G, et al. Association between infection with Helicobacter pylori and Chlamydia pneumoniae and risk of ischemic stroke subtypes:results from a population-based case-control study. Stroke 2001;32:2253-8.
Mendall MA, Goggin PM, Molineaux N, Levy J, Toosy T, Strachan D, et al. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994;71:437-9.
Park MJ, Choi SH, Kim D, Kang SJ, Chung SJ, Choi SY, et al. Association between Helicobacter pylori seropositivity and the coronary artery calcium score in a screening population. Gut Liver 2011;5:321-7.
Bouwman JJM, Visseren FLJ, Bouter KP, Diepersloot RJA. Infection-induced inflammatory response of adipocytes in vitro. Int J Obes (Lond) 2008;32:892-901.
Nabipour I, Larijani B, Beigi S, Jafari SM, Amiri M, Assadi M, et al. Relationship among insulin like growth factor I concentrations, bone mineral density, and biochemical markers of bone turnover in postmenopausal women: a population-based study. Menopause 2008;15:934-9.
Di Pietro M, Filardo S, DeSantis F, Sessa R. Chlamydia pneumoniae infection in atherosclerotic lesion development through oxidative stress:a brief overview.Int J Mol Sci 2013;14:15105-20.
Kuo C, Campbell LA. Detection of Chlamydia pneumoniae in arterial tissues. J Infect Dis
;181:S432-6.
Mei CL, He P, Cheng B, Liu W, Wang YF, Wan JJ. Chlamydia pneumoniae induces macrophage-derived foam cell formation via PPAR alpha and PPAR gamma- dependent pathways. Cell Biol Int 2009;33:301-8.
Cheng B, Wu X, Sun S, Wu Q, Mei C, Xu Q, et al.MAPK-PPARα/γ signal transduction pathways are
involved in Chlamydia pneumoniae-induced macrophage –derived foam cell formation. Microb Pathog 2014;69-70:1-8.
Ouchi N, Kihara S, AritaY, Nishida M, Matsuyama A, Okamoto Y, et al. Adipocyte-derived plasma protein, adiponectin, suppress lipid accumulation and class A receptor expression in human monocyte-derived macrophages. Circulation 2001;103:1057-63.
Kim YH, Choi SY, Suh JH, Kim TK, Seung KB, Wang YP, et al. The effect of Chlamydia pneumoniae on the expression of peroxisome proliferator-activated receptor-γ in vascular smooth muscle cells. Yonsei Med J 2008;49:230-6.
Duval C, Chinetti G, Trottein F, Fruchart JC, Staels B.The role of PPARs in atherosclerosis. Trends Mol Med 2002;8:422-30.
Hsueh WA, Jackson S, Law RE. Control of vascular cell proliferation and migration by PPAR-gamma:a new approach to the macrovascular complication of diabetes. Diabetes Care 2001;24:392-7.
Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, et al. Induction of adiponectin ,a fat- derived antidiabetic and anti atherogenic factor, by nuclear receptors. Diabetes 2003;52:1655-63.
Tsuchida A, Yamauchi T, Takekawa S, Hada Y, Ito Y, Mak T, et al. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue:comparison of PPA Ralpha, PPAR gamma, and their combination. Diabetes 2005;54:3358-70.
Shi Y, Liu Y, Murdin A, Raudonikiene-Mancevski A, Ayach BB, Yu Z, et al. Chlamydophila pneumoniae inhibits differentiation of progenitor adipose cells and impairs insulin signaling. J Infect Dis 2008;197:439-48.
Wolfing B, Buechler C, Weigert J, Neumeier M, Aslanidis C, Schoelmerich J, et al. Effects of the new C1q/TNF-related protein(CTRP-3) ”cartonectin” on the adipocytic secretion of adipokines. Obesity (Silver Spring) 2008;16:1481-6.
Schmid A, Kopp A, Hanses F, Bala M, Muller Schaffler A. The novel adipokine C1q/TNF-related protein-3 is expressed in human adipocytes and regulated by metabolic and infection-related parameters. Exp Clin Endocrinol Diabetes 2012;120:611-7.
Ando T, IshikawaT, Takagi T, Imamoto E, Kishimoto E, Okajima A, et al. Impact of Helicobacter pylori eradication on circulating adiponectin in humans. Helicobacter 2013;18:158-64.
Vafaeimanesh J, Heidari A, Effatpanah M, Parham M.Serum adiponectin level in diabetic patients with and without Helicobacter pylori infection:is there any difference? Sci World J 2014;2014:402685.
Polyzos SA, Kountouras J, Zavos C, Pyrrou N, Tantsi N.Helicobacter pylori infection and serum adiponectin. Helicobacter 2013;18:321-2.
Watson C, Alp NJ. Role of Chlamydia pneumoniae in atherosclerosis. Clin Sci (Lond) 2008;114:509-531.
Davidson M, Kuo CC, Middaugh JP, Campbell LA, Wang SP, Newman WP, et al. Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation 1998;98:628-33.
| Files | ||
| Issue | Vol 54, No 12 (2016) | |
| Section | Original Article(s) | |
| Keywords | ||
| Chlamydia pneumoniae Helicobacter pylori Adiponectin Visfatin Omentin-1 | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
